{
    "xml": "<topic id=\"PHP5581\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/trastuzumab\" basename=\"trastuzumab\" title=\"TRASTUZUMAB\">\n<title>TRASTUZUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1290\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/trastuzumab\">Trastuzumab</xref>\n</p>\n<data name=\"vtmid\">327397006</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872447286\" title=\"Monoclonal antibodies (antineoplastic)\">Monoclonal antibodies (antineoplastic)</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP53874\" outputclass=\"indicationsAndDose\" rev=\"1.20\" parent=\"/drugs/trastuzumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of early breast cancer which overexpresses human epidermal growth factor receptor-2 (HER2) (initiated by a specialist)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of metastatic breast cancer in patients with HER2-positive tumours who have not received chemotherapy for metastatic breast cancer and in whom anthracycline treatment is inappropriate (in combination with paclitaxel or docetaxel) (initiated by a specialist)</p>\n<p outputclass=\"therapeuticIndication\">Treatment of metastatic breast cancer in postmenopausal patients with hormone-receptor positive HER2-positive tumours not previously treated with trastuzumab (in combination with an aromatase inhibitor) (initiated by a specialist)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion or by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Monotherapy for metastatic breast cancer in patients with tumours that overexpress HER2 who have received at least 2 chemotherapy regimens including, where appropriate, an anthracycline and a taxane (initiated by a specialist)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion or by subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Women with oestrogen-receptor-positive breast cancer should also have received hormonal therapy (consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of metastatic gastric cancer in patients with HER2-positive tumours who have not received treatment for metastatic gastric cancer (in combination with capecitabine or fluorouracil and cisplatin) (initiated by a specialist)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53931\" outputclass=\"contraindications\" rev=\"1.7\" parent=\"/drugs/trastuzumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Severe dyspnoea at rest</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53950\" outputclass=\"cautions\" rev=\"1.10\" parent=\"/drugs/trastuzumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Coronary artery disease</ph>; <ph outputclass=\"caution\">history of hypertension</ph>; <ph outputclass=\"caution\">symptomatic heart failure</ph>; <ph outputclass=\"caution\">uncontrolled arrhythmias</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53862\" outputclass=\"interactions\" rev=\"1.12\" parent=\"/drugs/trastuzumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (trastuzumab)</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Use with anthracyclines</p>\n<p>Concomitant use of trastuzumab with anthracyclines is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If an anthracycline needs to be used, cardiac function should be monitored closely.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53738\" outputclass=\"sideEffects\" rev=\"1.16\" parent=\"/drugs/trastuzumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Acne</ph>; <ph outputclass=\"sideEffect\">alopecia</ph>; <ph outputclass=\"sideEffect\">alopecia</ph>; <ph outputclass=\"sideEffect\">anaphylaxis</ph>; <ph outputclass=\"sideEffect\">angioedema</ph>; <ph outputclass=\"sideEffect\">anxiety</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">arthritis</ph>; <ph outputclass=\"sideEffect\">asthenia</ph>; <ph outputclass=\"sideEffect\">bone pain</ph>; <ph outputclass=\"sideEffect\">bone-marrow suppression</ph>; <ph outputclass=\"sideEffect\">cardiotoxicity</ph>; <ph outputclass=\"sideEffect\">chest pain</ph>; <ph outputclass=\"sideEffect\">chills</ph>; <ph outputclass=\"sideEffect\">depression</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dry eye</ph>; <ph outputclass=\"sideEffect\">dry skin</ph>; <ph outputclass=\"sideEffect\">ecchymosis</ph>; <ph outputclass=\"sideEffect\">extravasation</ph>; <ph outputclass=\"sideEffect\">fever</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal symptoms</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">hepatitis</ph>; <ph outputclass=\"sideEffect\">hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">hypertension</ph>; <ph outputclass=\"sideEffect\">hypertonia</ph>; <ph outputclass=\"sideEffect\">hyperuricaemia</ph>; <ph outputclass=\"sideEffect\">hypotension</ph>; <ph outputclass=\"sideEffect\">increased lacrimation</ph>; <ph outputclass=\"sideEffect\">infection</ph>; <ph outputclass=\"sideEffect\">infusion-related side-effects (possibly delayed onset)</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">leg cramps</ph>; <ph outputclass=\"sideEffect\">malaise</ph>; <ph outputclass=\"sideEffect\">mastitis</ph>; <ph outputclass=\"sideEffect\">myalgia</ph>; <ph outputclass=\"sideEffect\">nail disorders</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">oedema</ph>; <ph outputclass=\"sideEffect\">oral mucositis</ph>; <ph outputclass=\"sideEffect\">paraesthesia</ph>; <ph outputclass=\"sideEffect\">paresis</ph>; <ph outputclass=\"sideEffect\">peripheral neuropathy</ph>; <ph outputclass=\"sideEffect\">pruritus</ph>; <ph outputclass=\"sideEffect\">pulmonary events (possibly delayed onset)</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">sweating</ph>; <ph outputclass=\"sideEffect\">taste disturbance</ph>; <ph outputclass=\"sideEffect\">thromboembolism</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">tumour lysis syndrome</ph>; <ph outputclass=\"sideEffect\">urticaria</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>; <ph outputclass=\"sideEffect\">weight loss</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53942\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/trastuzumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Exclude pregnancy before treatment with cytotoxic drugs.</p>\n<p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;effective contraception must be used during treatment and for 6 months after stopping.</p>\n<p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53835\" outputclass=\"pregnancy\" parent=\"/drugs/trastuzumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;oligohydramnios reported.</p>\n<p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p>\n<p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53961\" outputclass=\"breastFeeding\" parent=\"/drugs/trastuzumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid breast-feeding during treatment and for 7 months afterwards.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53701\" outputclass=\"monitoringRequirements\" parent=\"/drugs/trastuzumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p outputclass=\"title\">Cardiotoxicity</p>\n<p>Monitor cardiac function before and during treatment&#8212;for details of monitoring and managing cardiotoxicity, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53974\" outputclass=\"directionsForAdministration\" rev=\"1.7\" parent=\"/drugs/trastuzumab\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>Resuscitation facilities should be available during administration of trastuzumab.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP60054\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.16\" parent=\"/drugs/trastuzumab\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>When prescribing, dispensing or administering, check that this is the correct preparation&#8212;trastuzumab is <b>not</b> interchangeable with trastuzumab emtansine.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP53665\" outputclass=\"nationalFunding\" rev=\"1.22\" parent=\"/drugs/trastuzumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA34</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002)</p>\r\n<p>Trastuzumab in combination with paclitaxel is recommended as an option for patients with tumours expressing human epidermal growth factor receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer, and in whom anthracycline treatment is inappropriate.</p>\r\n<p>Trastuzumab monotherapy is recommended as an option for patients with tumours expressing HER2 scored at levels of 3+ who have received at least two chemotherapy regimens for metastatic breast cancer. Prior chemotherapy must have included at least an anthracycline and a taxane where these treatments are appropriate. It should also have included hormonal therapy in suitable oestrogen-receptor-positive patients.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA34\">www.nice.org.uk/TA34</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA107</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (August 2006)</p>\r\n<p>Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as an option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA107\">www.nice.org.uk/TA107</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA208</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010)</p>\r\n<p> Trastuzumab in combination with cisplatin and capecitabine or fluorouracil is recommended for human epidermal growth factor receptor-2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who:</p>\r\n<ul>\r\n<li>have not received treatment for metastatic disease <b>and</b>\r\n</li>\r\n<li>have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3.</li>\r\n</ul>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA208\">www.nice.org.uk/TA208</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA257</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012)</p>\r\n<p>Lapatinib or trastuzumab in combination with an aromatase inhibitor is <b>not</b> recommended for first-line treatment in postmenopausal women of metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).</p>\r\n<p>Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA257\">www.nice.org.uk/TA257</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP5581-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/trastuzumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75469\" title=\"Solution for injection\" namespace=\"/drugs/trastuzumab/solution-for-injection\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75463\" title=\"Powder for solution for infusion\" namespace=\"/drugs/trastuzumab/powder-for-solution-for-infusion\">Powder for solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78591\" namespace=\"/treatment-summaries/hormones-malignant-disease\" title=\"Hormones, malignant disease\" count=\"3\" rel=\"backlink\">Hormones, malignant disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1290\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/trastuzumab\" title=\"Trastuzumab\" count=\"1\" rel=\"link\">Trastuzumab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75469\" namespace=\"/drugs/trastuzumab/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75463\" namespace=\"/drugs/trastuzumab/powder-for-solution-for-infusion\" title=\"Powder for solution for infusion\" count=\"1\" rel=\"link\">Powder for solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP5581",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/trastuzumab",
    "basename": "trastuzumab",
    "title": "TRASTUZUMAB",
    "interactants": [
        {
            "id": "bnf_int_1290",
            "label": "Trastuzumab"
        }
    ],
    "vtmid": "327397006",
    "drugClassification": [
        "Monoclonal antibodies (antineoplastic)"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of early breast cancer which overexpresses human epidermal growth factor receptor-2 (HER2) (initiated by a specialist)",
                        "html": "Treatment of early breast cancer which overexpresses human epidermal growth factor receptor-2 (HER2) (initiated by a specialist)"
                    },
                    {
                        "textContent": "Treatment of metastatic breast cancer in patients with HER2-positive tumours who have not received chemotherapy for metastatic breast cancer and in whom anthracycline treatment is inappropriate (in combination with paclitaxel or docetaxel) (initiated by a specialist)",
                        "html": "Treatment of metastatic breast cancer in patients with HER2-positive tumours who have not received chemotherapy for metastatic breast cancer and in whom anthracycline treatment is inappropriate (in combination with paclitaxel or docetaxel) (initiated by a specialist)"
                    },
                    {
                        "textContent": "Treatment of metastatic breast cancer in postmenopausal patients with hormone-receptor positive HER2-positive tumours not previously treated with trastuzumab (in combination with an aromatase inhibitor) (initiated by a specialist)",
                        "html": "Treatment of metastatic breast cancer in postmenopausal patients with hormone-receptor positive HER2-positive tumours not previously treated with trastuzumab (in combination with an aromatase inhibitor) (initiated by a specialist)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion or subcutaneous injection"
                    ],
                    "textContent": "By intravenous infusion or by subcutaneous injection",
                    "html": "By intravenous infusion or by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Monotherapy for metastatic breast cancer in patients with tumours that overexpress HER2 who have received at least 2 chemotherapy regimens including, where appropriate, an anthracycline and a taxane (initiated by a specialist)",
                        "html": "Monotherapy for metastatic breast cancer in patients with tumours that overexpress HER2 who have received at least 2 chemotherapy regimens including, where appropriate, an anthracycline and a taxane (initiated by a specialist)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion or subcutaneous injection"
                    ],
                    "textContent": "By intravenous infusion or by subcutaneous injection",
                    "html": "By intravenous infusion or by subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "Women with oestrogen-receptor-positive breast cancer should also have received hormonal therapy (consult product literature or local protocols).",
                        "html": "<p>Women with oestrogen-receptor-positive breast cancer should also have received hormonal therapy (consult product literature or local protocols).</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of metastatic gastric cancer in patients with HER2-positive tumours who have not received treatment for metastatic gastric cancer (in combination with capecitabine or fluorouracil and cisplatin) (initiated by a specialist)",
                        "html": "Treatment of metastatic gastric cancer in patients with HER2-positive tumours who have not received treatment for metastatic gastric cancer (in combination with capecitabine or fluorouracil and cisplatin) (initiated by a specialist)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Severe dyspnoea at rest",
                "html": "Severe dyspnoea at rest"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Coronary artery disease",
                "html": "Coronary artery disease"
            },
            {
                "type": "cautions",
                "textContent": "history of hypertension",
                "html": "history of hypertension"
            },
            {
                "type": "cautions",
                "textContent": "symptomatic heart failure",
                "html": "symptomatic heart failure"
            },
            {
                "type": "cautions",
                "textContent": "uncontrolled arrhythmias",
                "html": "uncontrolled arrhythmias"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (trastuzumab)",
                "html": "<p>Appendix 1 (trastuzumab)</p>"
            },
            {
                "type": "general",
                "title": "Use with anthracyclines",
                "textContent": "Concomitant use of trastuzumab with anthracyclines is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If an anthracycline needs to be used, cardiac function should be monitored closely.",
                "html": "<p>Concomitant use of trastuzumab with anthracyclines is associated with cardiotoxicity. The use of anthracyclines even after stopping trastuzumab can increase the risk of cardiotoxicity and if possible should be avoided for up to 24 weeks. If an anthracycline needs to be used, cardiac function should be monitored closely.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Acne",
                        "html": "Acne",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "alopecia",
                        "html": "alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "alopecia",
                        "html": "alopecia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anaphylaxis",
                        "html": "anaphylaxis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "angioedema",
                        "html": "angioedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "anxiety",
                        "html": "anxiety",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "arthritis",
                        "html": "arthritis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "asthenia",
                        "html": "asthenia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone pain",
                        "html": "bone pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "bone-marrow suppression",
                        "html": "bone-marrow suppression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "cardiotoxicity",
                        "html": "cardiotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "chest pain",
                        "html": "chest pain",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "chills",
                        "html": "chills",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "depression",
                        "html": "depression",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dry eye",
                        "html": "dry eye",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "dry skin",
                        "html": "dry skin",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "ecchymosis",
                        "html": "ecchymosis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "extravasation",
                        "html": "extravasation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fever",
                        "html": "fever",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gastro-intestinal symptoms",
                        "html": "gastro-intestinal symptoms",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatitis",
                        "html": "hepatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypersensitivity reactions",
                        "html": "hypersensitivity reactions",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypertension",
                        "html": "hypertension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypertonia",
                        "html": "hypertonia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hyperuricaemia",
                        "html": "hyperuricaemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hypotension",
                        "html": "hypotension",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "increased lacrimation",
                        "html": "increased lacrimation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "infection",
                        "html": "infection",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "infusion-related side-effects (possibly delayed onset)",
                        "html": "infusion-related side-effects (possibly delayed onset)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "leg cramps",
                        "html": "leg cramps",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "malaise",
                        "html": "malaise",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "mastitis",
                        "html": "mastitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "myalgia",
                        "html": "myalgia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nail disorders",
                        "html": "nail disorders",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oedema",
                        "html": "oedema",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "oral mucositis",
                        "html": "oral mucositis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "paraesthesia",
                        "html": "paraesthesia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "paresis",
                        "html": "paresis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "peripheral neuropathy",
                        "html": "peripheral neuropathy",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pruritus",
                        "html": "pruritus",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "pulmonary events (possibly delayed onset)",
                        "html": "pulmonary events (possibly delayed onset)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "sweating",
                        "html": "sweating",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "taste disturbance",
                        "html": "taste disturbance",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "thromboembolism",
                        "html": "thromboembolism",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "tumour lysis syndrome",
                        "html": "tumour lysis syndrome",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "urticaria",
                        "html": "urticaria",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "weight loss",
                        "html": "weight loss",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Exclude pregnancy before treatment with cytotoxic drugs.\n\nContraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;effective contraception must be used during treatment and for 6 months after stopping.\n\nRegimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.",
                "html": "<p>Exclude pregnancy before treatment with cytotoxic drugs.</p><p>Contraceptive advice should be given to men and women before cytotoxic therapy begins (and should cover the duration of contraception required after therapy has ended)&#8212;effective contraception must be used during treatment and for 6 months after stopping.</p><p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;oligohydramnios reported.\n\nMost cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.\n\nConsiderable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.",
                "html": "<p>Manufacturer advises avoid&#8212;oligohydramnios reported.</p><p>Most cytotoxic drugs are teratogenic and should not be administered during pregnancy, especially during the first trimester.</p><p>Considerable caution is necessary if a pregnant woman presents with cancer requiring chemotherapy, and specialist advice should always be sought.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid breast-feeding during treatment and for 7 months afterwards.",
                "html": "<p>Avoid breast-feeding during treatment and for 7 months afterwards.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "title": "Cardiotoxicity",
                "textContent": "Monitor cardiac function before and during treatment&#8212;for details of monitoring and managing cardiotoxicity, consult product literature.",
                "html": "<p>Monitor cardiac function before and during treatment&#8212;for details of monitoring and managing cardiotoxicity, consult product literature.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Resuscitation facilities should be available during administration of trastuzumab.",
                "html": "<p>Resuscitation facilities should be available during administration of trastuzumab.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "When prescribing, dispensing or administering, check that this is the correct preparation&#8212;trastuzumab is not interchangeable with trastuzumab emtansine.",
                "html": "<p>When prescribing, dispensing or administering, check that this is the correct preparation&#8212;trastuzumab is <b>not</b> interchangeable with trastuzumab emtansine.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA34",
                        "label": "www.nice.org.uk/TA34"
                    }
                ],
                "fundingIdentifier": "NICE TA34",
                "textContent": "Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002) Trastuzumab in combination with paclitaxel is recommended as an option for patients with tumours expressing human epidermal growth factor receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer, and in whom anthracycline treatment is inappropriate. Trastuzumab monotherapy is recommended as an option for patients with tumours expressing HER2 scored at levels of 3+ who have received at least two chemotherapy regimens for metastatic breast cancer. Prior chemotherapy must have included at least an anthracycline and a taxane where these treatments are appropriate. It should also have included hormonal therapy in suitable oestrogen-receptor-positive patients.\n\nwww.nice.org.uk/TA34",
                "html": "<p outputclass=\"title\">Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002)</p> <p>Trastuzumab in combination with paclitaxel is recommended as an option for patients with tumours expressing human epidermal growth factor receptor 2 (HER2) scored at levels of 3+ who have not received chemotherapy for metastatic breast cancer, and in whom anthracycline treatment is inappropriate.</p> <p>Trastuzumab monotherapy is recommended as an option for patients with tumours expressing HER2 scored at levels of 3+ who have received at least two chemotherapy regimens for metastatic breast cancer. Prior chemotherapy must have included at least an anthracycline and a taxane where these treatments are appropriate. It should also have included hormonal therapy in suitable oestrogen-receptor-positive patients.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA34\">www.nice.org.uk/TA34</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA107",
                        "label": "www.nice.org.uk/TA107"
                    }
                ],
                "fundingIdentifier": "NICE TA107",
                "textContent": "Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (August 2006) Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as an option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).\n\nwww.nice.org.uk/TA107",
                "html": "<p outputclass=\"title\">Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (August 2006)</p> <p>Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as an option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA107\">www.nice.org.uk/TA107</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA208",
                        "label": "www.nice.org.uk/TA208"
                    }
                ],
                "fundingIdentifier": "NICE TA208",
                "textContent": "Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010) Trastuzumab in combination with cisplatin and capecitabine or fluorouracil is recommended for human epidermal growth factor receptor-2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who: have not received treatment for metastatic disease and have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3.\n\nwww.nice.org.uk/TA208",
                "html": "<p outputclass=\"title\">Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010)</p> <p> Trastuzumab in combination with cisplatin and capecitabine or fluorouracil is recommended for human epidermal growth factor receptor-2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction in patients who:</p> <ul> <li>have not received treatment for metastatic disease <b>and</b> </li> <li>have tumours expressing high levels of HER2 as defined by a positive immunohistochemistry score of 3.</li> </ul><xref format=\"html\" href=\"http://www.nice.org.uk/TA208\">www.nice.org.uk/TA208</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA257",
                        "label": "www.nice.org.uk/TA257"
                    }
                ],
                "fundingIdentifier": "NICE TA257",
                "textContent": "Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012) Lapatinib or trastuzumab in combination with an aromatase inhibitor is not recommended for first-line treatment in postmenopausal women of metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2). Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA257",
                "html": "<p outputclass=\"title\">Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012)</p> <p>Lapatinib or trastuzumab in combination with an aromatase inhibitor is <b>not</b> recommended for first-line treatment in postmenopausal women of metastatic hormone-receptor-positive breast cancer that overexpresses human epidermal growth factor receptor 2 (HER2).</p> <p>Postmenopausal women currently receiving lapatinib or trastuzumab in combination with an aromatase inhibitor for this indication should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA257\">www.nice.org.uk/TA257</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75469",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75463",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78591",
                "label": "Hormones, malignant disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1290",
                "label": "Trastuzumab",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75469",
                "label": "Solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75463",
                "label": "Powder for solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}